Merck to Acquire Pandion Therapeutics

Merck, known as MSD outside of the United States and Canada, and Pandion Therapeutics, Inc. announced that the companies have entered into a definitive agreement, under which Merck, through a subsidiary, will acquire Pandion, a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, for $60 per share in cash. Read more.